The Bull Rankings scorecard — our quality-growth score is 57.5 / 100, built from three pillars scored 0–100: Quality 77, Growth 78, Value 31 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 14% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Amgen’s market price of $433.73 is already demanding a 14% annual free‑cash‑flow growth (in year one, slowing to 3% a year by year ten), according to our reverse‑DCF. That is far above the 9.1% revenue growth it posted YoY. The gap tells us the market is pricing in faster expansion than the business just delivered. Yet the same model hands Amgen a Value pillar of 31, the weakest of the three. A low value score means the stock is expensive relative to peers, and the 14% implied growth is an optimism premium that the fundamentals don’t fully justify. The stronger Growth pillar (78) and a solid Quality score (77) keep the overall quality‑growth rating at 57.5, but the weak Value score makes the current price a stretch. In short, the market is over‑optimistic; the thesis is that AMGN is overvalued at today’s level.
What the business actually is
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. Its flagship biologics include Enbrel for rheumatoid arthritis and related conditions, Otezla for plaque psoriasis and Behçet’s disease, Prolia for postmenopausal osteoporosis, XGEVA to prevent skeletal events, Repatha for cardiovascular risk reduction, Nplate for immune thrombocytopenia, and KYPROLIS for relapsed or refractory multiple myeloma. These products generate the bulk of revenue, with Enbrel and Prolia historically anchoring the franchise. The company sells primarily to hospitals, specialty pharmacies, and large health systems that manage chronic, high‑cost diseases.
Why it can (or can't) keep compounding
Amgen’s 23% profit margin and ROE of 74.8% speak to a business that converts earnings into shareholder returns with exceptional efficiency. The high ROE owes much to a thin equity base after years of buybacks and debt‑funded deals, though biologics do need relatively modest additional investment once approved. The beta of 0.41 means the stock moves little with the market. The Bull Rankings model flags a dividend raise, indicating confidence in cash generation and a willingness to return capital. That dividend lift, combined with a pipeline anchored by biologics that are hard to replicate due to complex manufacturing and extensive regulatory barriers, creates a moat that competitors cannot breach quickly. The high debt‑to‑equity of 4.9 is the balance sheet’s weak spot, though steady cash flow keeps it serviceable.
The valuation question
At a PE of 26.9, Amgen trades near the sector median, while the analyst consensus 1‑yr target of $388.48 sits well below today’s price, implying a downside of roughly 10%. The reverse‑DCF tells us the market expects 14% free‑cash‑flow growth (in year one, slowing to 3% a year by year ten)—significantly higher than the 9.1% revenue growth reported YoY. This mismatch signals that the current multiple is built on expectations of either breakthrough launches or accelerated uptake of existing products that have not yet materialized. The Value pillar of 31 confirms that the stock is expensive relative to peers, and the Growth (78) and Quality (77) pillars are where the model sees strength. In effect, the price is already pricing in a growth premium that exceeds the company’s demonstrated trajectory.
The bear case
Skeptics can point to the low Value score (31) as a red flag: the market is demanding a growth rate that outpaces historical performance. If Amgen’s pipeline stalls or if biosimilar competition erodes Enbrel and Prolia revenues, the 14% implied growth becomes unattainable, forcing a price correction toward the consensus target. The debt‑to‑equity of 4.9 is high, and that leverage that could become a drag if cash flow slows. A concrete confirmation of the bear view would be a missed dividend increase or a cut, which would signal that management no longer expects the cash cushion needed to sustain the aggressive growth assumptions baked into the price.
What would change our mind
First, a revenue growth acceleration to double digits (above 12%) sustained over the next two quarters would narrow the gap between actual and implied growth, making the premium more palatable. Second, an improvement in the Value pillar—for example, if the model’s value score rose above 50 due to a lower PE or higher free‑cash‑flow yield—would indicate the stock is less overpriced. Third, a confirmation of the dividend raise would reinforce the cash‑flow narrative and could justify the 14% growth assumption. Until one of these conditions materializes, the current pricing remains stretched.